Objective: The primary objective was to investigate the long-term survival of patients who underwent single-vessel coronary revascularization with minimally invasive direct coronary artery bypass surgery with or without hybrid revascularization. The secondary outcome measures were repeat revascularization either by coronary artery bypass grafting or by percutaneous coronary intervention and the incidence of myocardial infarction or recurrent angina. Methods: This is a retrospective study of prospectively collected data of patients who underwent minimally invasive direct coronary artery bypass procedure in our center between January 2001 and December 2015. Procedures were performed either through small left anterolateral thoracotomy or lower midline sternotomy. Results: A total of 182 patients were identified: 100 underwent minimally invasive direct coronary artery bypass to the left anterior descending artery and 82 underwent hybrid revascularization (percutaneous coronary intervention to coronary arteries other than the left anterior descending artery along with minimally invasive direct coronary artery bypass to the left anterior descending artery). The mean ± SD age was 62 ± 10.1 years. Preoperatively 82% were male, and 72.5% patients had good left ventricular function. The median follow-up period was 10.9 years. There was no inhospital or 30-day mortality. The 10-year actuarial survival was 84.8%. Freedom from repeat revascularization was 98.9% at 1 year and 89.9% at 10 years. At follow-up, freedom from myocardial infarction was 96.7% whereas freedom from angina was 92.9%. Conclusions: Within the limitations imposed by retrospective analyses, our study demonstrates excellent long-term outcome in patients undergoing minimally invasive direct coronary artery bypass with or without hybrid revascularization. For isolated left anterior descending artery disease minimally invasive direct coronary artery bypass should be considered, whereas hybrid revascularization (percutaneous coronary intervention and minimally invasive direct coronary artery bypass) should be considered for multivessel disease.
C oronary artery bypass grafting (CABG) is considered the criterion standard for revascularization in patients with multivessel disease involving the left anterior descending artery (LAD). 1, 2 Although the prognostic advantage is mainly attributed to the left internal thoracic artery (LITA) to LAD graft, all diseased coronary arteries are also bypassed. [3] [4] [5] For patients with low syntax score percutaneous coronary intervention (PCI) is considered a viable alternative. 1 Traditionally, these patients undergo open surgery through a median sternotomy, without or without cardiopulmonary bypass. More than two decades ago, minimally invasive direct coronary artery bypass (MIDCAB) grafting techniques were developed for the surgical management of patients with isolated LAD disease. 6, 7 For the past two decades, this technique has evolved further with technological advances such as endoscopic harvesting of the LITA, robotically assisted direct coronary artery bypass grafting (RADCAB), and endoscopically assisted coronary artery bypass grafting.
After the development of drug-eluting stents, hybrid approach using MIDCAB to the LAD and simultaneous PCI to non-LAD target vessels have been used in revascularizing selected patients with multivessel disease. [8] [9] [10] Despite these advances and potential benefits for patients, MIDCAB continues not to be widely practiced. One reason for this is the uncertainty of long-term outcomes, in comparison with more established and widespread revascularization techniques. The primary objective of our study was to investigate the long-term survival of patients who underwent surgical single-vessel coronary revascularization with MIDCAB surgery. The secondary outcome measures were repeat revascularization either by CABG PCI and the incidence of myocardial infarction or recurrent angina.
METHODS

Study Population
This is a retrospective study of prospectively collected data of patients who underwent the MIDCAB procedure in a single center between January 2001 and December 2015.
Patients were identified from our prospectively maintained operative database. Demographic and operative data were retrieved from the database. Patient electronic patient records were subsequently reviewed to obtain additional outcome and survival data and to cross-check accuracy of the retrieved data. Preoperatively, a dedicated heart multidisciplinary team discussed all cases and formulated a management strategy.
Patients were considered suitable for hybrid revascularization if they had multivessel disease not suitable for PCI to the LAD or with occluded LAD or if they had multivessel disease where the non-LAD targets were deemed suitable for PCI. Contraindications included the following: patients with severe pulmonary disease, patients requiring concomitant valvular surgery, and patients requiring redo procedures.
Patients with isolated LAD disease not suitable for PCI underwent MIDCAB, whereas the patients with multivessel disease not suitable for PCI to the LAD underwent MIDCAB followed by PCI to the diseased non-LAD coronary arteries 48 to 72 hours after surgery or before discharge (hybrid procedure). For patients in the hybrid revascularization group, MIDCAB was performed first followed by PCI before discharge or within 6 weeks after the surgical procedure.
Patients with severe pulmonary disease or requiring concomitant valvular surgery or redo procedures were considered unsuitable for MIDCAB.
Operative Details
Minimally invasive direct coronary artery bypass was performed predominantly by two consultant surgeons. The procedures were performed either through a small anterolateral thoracotomy or a lower midline sternotomy.
Anesthesia
A double-lumen endotracheal tube was inserted for left thoracotomy approach, whereas a single-lumen intubation was used for the sternotomy approach, with intraoperative monitoring as used for routine cardiac surgery. All patients have external defibrillator pads placed before starting surgery. A cardiopulmonary bypass circuit was kept stand-by for all cases, and intraoperative cell salvage used.
Anticoagulation was achieved with 150 U/kg of heparin. If required, heparin was supplemented to maintain the activated clotting time greater than 400 seconds and was reversed by protamine at the end of the procedure. Throughout the procedure, the mean arterial pressure was maintained greater than 50 mm Hg by intravenous fluids, optimal use of vasoconstrictors, or both.
Midline Sternotomy Approach
This is done with a 5-cm skin incision that is undermined cranially and caudally to allow for division of the sternum from the 4th interspace down. If necessary, the left hemisternum is transected to improve exposure. After incision of the pericardium, the target vessel is identified to ensure suitability for MIDCAB (an intramyocardial vessel is an absolute contraindication for this technique). After that, a pedicled LITA is harvested and the patient fully heparinized. A suction-type (Octopus, Medtronic, Inc, Minneapolis, MN USA) mechanical stabilizer is used to stabilize the target coronary artery and the coronary anastomosis constructed with 7-0 polypropylene sutures (Prolene, Johnson and Johnson, New Brunswick, NJ USA) using an intracoronary shunt.
Thoracotomy Approach
After the left lung is deflated, an incision was made in the fourth intercostal space. As necessary, the thoracotomy was extended a few centimeters anteriorly or posteriorly to gain exposure of the target coronary vessel. The pericardium was opened carefully preserving the phrenic nerve. Careful and limited dissection was performed to locate the target vessel and confirm suitability. Then, a pedicled LIMA was harvested of appropriate length. The distal anastomosis was completed using endovascular shunts. Distal anastomoses were completed with running 7-0 or 8-0 polypropylene sutures depending on the size and quality of the target vessel.
PERCUTANEOUS CORONARY INTERVENTION
For patients in the hybrid revascularization group, PCI was usually performed before hospital discharge. In 54 (65.8%) of the 82 patients, stenting was performed within the first 72 hours after surgery. The range was 1 to 34 days after surgery. In 75 patients (91.5%), a single coronary artery was stented, most frequently the right coronary artery (37, 45.1%), the first diagonal branch (19, 23 .2%), the left circumfl ex artery (15, 18.3%), and the obtuse marginal artery (4, 4.9%). The remaining patients had two vessels stented. Most patients received a drug-eluting stent (65, 79.3%), with the remaining receiving a bare metal stent (17, 20.7%).
Postoperative Management
Postoperatively patients were transferred to the intensive care unit. Aspirin 300 mg was administered 6 hours postoperatively by the per-rectal route if not bleeding, and dual antiplatelet therapy commenced on the first postoperative day. Dual antiplatelet therapy comprised aspirin and clopidogrel. For patients undergoing PCI, dual antiplatelet therapy is our standard cardiology protocol for 1-year poststenting. For surgical patients, postoperative dual antiplatelet therapy was commenced according to the preference of the surgeon for 6 months, reducing to single antiplatelet therapy thereafter.
Surgical follow-up was performed at 6 weeks, and thereafter, regular follow-up was performed by their local referring cardiologist.
Outcome Measures
The primary outcomes were in-hospital operative mortality and late mortality (time to all-cause mortality from intervention to end of data collection). Mortality data were obtained from the Office for National Statistics death certification records, linked to the National Adult Cardiac Surgery Audit database in January 2017.
Secondary outcomes included incidence of repeat revascularization, myocardial infarction, and presence of symptoms related to ischemic heart disease. Follow-up information was obtained from hospital databases as well as from telephone interview of the patients.
Data Analysis
Data were analyzed using GraphPad Prism 5.03 (GraphPad Software, Inc, San Diego, CA USA). The Kaplan-Meier method was used to plot patient survival rates and revascularization rates. Paired data analysis was performed using Student t test for continuous variables and χ 2 for categorical variables if all expected counts were greater than five or Fisher exact test otherwise. A P value of less than 0.05 was considered statistically significant.
RESULTS
A total of 182 patients were identified who had undergone MIDCAB at our center between January 2001 and December 2015. Of these, 100 patients underwent MIDCAB alone and the remaining 82 underwent hybrid revascularization with a MIDCAB to the LAD coronary artery and concomitant percutaneous coronary stenting to other diseased coronary arteries.
Demographics of the patients are summarized in Table 1 . The mean ± SD age was 62 (10.1) years, and most were male (82%). Preoperatively, 72.5% patients had good left ventricular function. Patients undergoing hybrid revascularization were older than those undergoing MIDCAB alone and tended to have more significant left ventricular impairment. None of the cases required conversion to full sternotomy. Comorbidities were similar between the groups. Those patients undergoing hybrid revascularization had higher EuroSCORE.
Patient Survival
There was no in-hospital or 30-day mortality. Median follow-up of the cohort is 10.9 years. Ten-year actuarial survival was 84.8% (Fig. 1) . Patients undergoing hybrid revascularization had a significantly inferior long-term survival than those undergoing MIDCAB (75.6% vs 91.9%, P = 0.003), likely reflecting their increased age, and possibly sequelae of increased severity of coronary artery disease and poorer ventricular function (Fig. 2) .
Freedom From Angina and Myocardial Infarction
Thirteen patients presented to hospital with recurrent angina, and a further six were treated for myocardial infarction for the period of follow-up. This is over the median follow-up period of 10.9 years. The overall freedom from angina was 92.9% and freedom from myocardial infarction 96.7%. There was no difference in the long-term freedom from angina (hybrid = 92.7% vs MIDCAB = 93%) or myocardial infarction (hybrid = 96.3% vs MIDCAB = 97%) between the two groups (Figs. 3, 4) . Patients treated for angina by their primary care physician without referral to the hospital are not included in this analysis.
Freedom From Repeat Revascularization
Freedom from revascularization for the cohort was excellent (1 year = 98.9%, 5 years = 97.2%, 10 years = 89.9%, 15 years = 87.7%) (Fig. 3) . There was no significant difference in freedom from revascularization (Fig. 4) between patients undergoing hybrid revascularization and those undergoing MIDCAB alone (P = 0.78).
Comparison Between Hybrid Revascularization and CABG
We identified 45 patients who underwent conventional CABG for the same period, matched on the basis of precise disease distribution, left ventricular function, and operating surgeon to 45 patients undergoing hybrid revascularization. The groups were similar in mean age (67 years CABG vs 65 years hybrid, P = 0.43), sex (76% CABG vs 68% hybrid were male, P = 0.67), mean EuroSCORE (P = 0.78), and median number of vessels revascularized (2 in both groups). Median postoperative stay in hybrid patients was shorter (5.5 vs 7 days, P = 0.04). There was no in-hospital or 30-day mortality in either group. Long-term survival was also equivalent between these two groups (P = 0.87).
DISCUSSION
Our study reports on long-term outcomes after MIDCAB with and without further hybrid revascularization. Our results are very encouraging with excellent long-term survival and freedom from myocardial infarction, angina, and repeat revascularization observed. These results confirm this management strategy to be safe and effective for patients with surgical LAD disease.
The primary objective of our study was to investigate whether good long-term survival outcome can be achieved by MIDCAB and hybrid revascularization. Our 10-year survival rate of 84.8% confirms that very good long-term survival can be achieved after MIDCAB revascularization. Patients undergoing MIDCAB alone had significantly better long-term survival compared with the hybrid group. However, patients in the hybrid group were older and had worse left ventricular function and multivessel disease when compared with the MIDCAB group, and therefore, inferior survival would be predicted.
Studies have previously reported on outcomes after MIDCAB. Some of these have focused on patients in whom standard surgery may be associated with high risk and have explored the more minimally invasive strategy as an alternative.
11-14
Gorki et al 11 have examined outcomes after MIDCAB in patients with low ejection fraction, reporting a 10-year survival of 36.9%. Sorm et al 12 reviewed outcomes in elderly patients, reporting a 5-year survival of those older than 70 years of 79.7%, and a similar survival for patients undergoing MIDCAB younger than 70 years. A propensity-matched analysis by Raja et al 15 comparing MIDCAB with full sternotomy for isolated LAD disease concluded that MIDCAB resulted in similar mid-term outcomes to open surgery at a mean follow-up of 6.2 years, with reduced early complications such as wound infection. Our data add to this body of evidence to emphasize that good long-term outcome to 10 and even 15 years can be achieved with low rates of coronary reintervention.
Despite advances in PCI technology resulting in reduced revascularization rates, it is clear that MIDCAB is superior to PCI for single-vessel LAD disease. A meta-analysis of 2885 patients from 12 studies comparing PCI with MIDCAB for revascularization of the LAD concluded that the PCI group had a significantly greater rate of major adverse cardiac and cerebrovascular events-specifically, a significantly greater reintervention rate from 6-month postprocedure, an effect that persists to beyond 10 years of follow-up. 16 Several studies have also demonstrated good long-term results with the use of RADCAB. 17, 18 However, lack of standardization, technical, logistic, and cost-related issues hinder the growth of RADCAB in the current era of financial constraints within public health services. 19 The LITA to LAD graft has the greatest positive prognostic significance after cardiac surgery with patency rates in excess of 90% at 10 years. 20 Minimally invasive direct coronary artery bypass evolved as a surgical strategy that is not only minimally invasive but additionally avoids the potential complications and side effects of cardiopulmonary bypass. One of the concerns with MIDCAB grafting is the question of long-term graft patency, anastomosing onto the beating heart through a small aperture. However, a meta-analysis revealed that a LITA graft to the LAD performed by MIDCAB with a stabilizer significantly reduced the stenosis rate from 9.6% to 3.7% (P = 0.002) and the combined occlusion and stenosis rate from 16% to 5.0% (P = 0.0001) when compared with series before the use of stabilizers. 21 In our series, we have used stabilizers throughout the study period that may have contributed to our excellent long-term results.
Although high patency rate for saphenous vein grafts using a "no-touch" technique has been reported, 22 most series report inferior patency rate for vein grafts when compared with arterial conduits, with 1-year failure rates of as high as 46%. 23 Improved outcomes after PCI using newer generation stents 24 have rejuvenated interest in hybrid revascularization. This has stemmed from the observation that the early restenosis rate of non-LAD vessels after PCI with drug eluting stent seems to be significantly less than the early occlusion rate of saphenous vein grafts. 24, 25 Suitable patients may, therefore, be able to have the best of both worlds: the prognostic advantage of LITA to LAD performed minimally invasively and PCI to other diseased arteries. 1 To date, there have not been any large randomized controlled studies examining the benefit of hybrid revascularization. However, several case series have suggested that this approach leads to improved survival than multivessel PCI and offers benefits in comparison with conventional CABG, namely, reduced stroke rate, infection rate, and recovery time. 8, 9, 26 Our study supports that good long-term outcomes can be achieved with hybrid revascularization, with low reintervention rates observed and good survival at later time points than have been previously reported.
Limitations
This is an observational study with retrospective analysis of prospectively collected data that has intrinsic limitations. Patients undergoing MIDCAB surgery were not randomized, and no comparison was made to a comparable cohort undergoing open surgery, which may limit generalizability of the results. The study did not perform follow-up angiography to assess long-term graft and stent patency, although this was not an objective of the study. This information will be very useful in assessment of this management strategy in the future.
CONCLUSIONS
Within the limitations imposed by retrospective analyses, our study demonstrates excellent long-term outcome in patients undergoing MIDCAB with or without hybrid revascularization. For isolated LAD artery disease, MIDCAB should be considered whereas hybrid revascularization (PCI and MIDCAB) should be considered for multivessel disease in selected group of patients, particularly those with a low SYNTAX score (<23).
We have entered an era where the multidisciplinary heart team concept has enabled cardiac surgeons to work in close cooperation with cardiologists to jointly decide which management approach is best for each individual patient. As our patient population grows older and becomes more complex, we should recognize the benefits offered by surgical strategies other than the standard "on-pump" full sternotomy CABG. Hybrid revascularization offers the best of both worlds for selected patient-minimally invasive LIMA to LAD grafting, with newer generation drugeluting stents to other target lesions. However, randomized controlled studies would be beneficial to directly compare outcomes.
